Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . RemeGen 荣昌 生物 RemeGen Co. , Ltd. * 榮昌 生物 製藥 ( 煙台 ) 股份有限公司 ( A joint stock company incorporated in the People's Republic of China with limited liability ) ( Stock Code : 9995 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2021 The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended June 30 , 2021 , together with the comparative figures for the same period in 2020 . BUSINESS HIGHLIGHTS As at the date of this announcement , we have made significant progress in advancing our product pipeline as well as business operations : The NMPA granted conditional marketing approval to telitacicept ( brand name : ) for the treatment of SLE in China in March 2021 , and we have begun commercial sales of this product . The NMPA granted conditional marketing approval to disitamab vedotin ( brand name : ☀ ☞® ) for the treatment of HER2 expressing locally advanced or metastatic GC in China in June 2021 , and we have begun commercial sales of this product since July 2021 . As of June 30 , 2021 , we have successfully established two independent sales teams for the products above , among which , there were 130 sales personnel in the autoimmune area , and 160 sales personnel in the oncology area . In June , 2021 , the NMPA has granted disitamab vedotin breakthrough therapy designation for the treatment of HER2 positive breast cancer with liver metastasis patients previously treated with trastuzumab and taxane . We are currently conducting Phase III clinical trial for this indication in China . In March 2021 , the Company was officially included in the Hang Seng Composite Index , indicating that the Company has fullfilled the relevant criteria for Southbound Trading . On June 2 , 2021 , the Company completed the H share full circulation by converting the 71,232,362 unlisted shares into H shares and these shares were listed on the Stock Exchange on June 3 , 2021 . 1